Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 4/2013

01-04-2013 | Letter to the Editor

Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

Authors: Siddhartha Ganguly, Manik Amin, Clint Divine, Omar S. Aljitawi, Sunil Abhyankar, Joseph P. McGuirk

Published in: Annals of Hematology | Issue 4/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Kumar L (1994) Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12:1710–1717PubMed
2.
Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G (2007) Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 31:257–259PubMedCrossRef
3.
Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P et al (2009) Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899–1905PubMedCrossRef
4.
de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23):5420–5431PubMedCrossRef
5.
Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45(5):872–876PubMedCrossRef
6.
Platzbecker U, Wermke M, Radke J, Oelsclaegel U, Seltmann F, Kiani A et al (2012) Azacytidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 36:381–389CrossRef
7.
Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–26778PubMedCrossRef
8.
Ravandi F, Kantarjian H, Cohen A, Davis M, O’Brien S, Anderlini P et al (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27:1221–1225PubMedCrossRef
9.
Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussière H, Tigaud I et al (2011) Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clin Lymphoma Myeloma Leuk 4:342–9CrossRef
Metadata
Title
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)
Authors
Siddhartha Ganguly
Manik Amin
Clint Divine
Omar S. Aljitawi
Sunil Abhyankar
Joseph P. McGuirk
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 4/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1607-y

Other articles of this Issue 4/2013

Annals of Hematology 4/2013 Go to the issue

Letter to the Editor

Limitation in the assessment of baseline lymphomatous bone marrow involvement by FDG-PET/CT scan

Original Article

Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia

Original Article

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Letter to the Editor

Histiocytic sarcoma simulating immune thrombocytopenic purpura

Letter to the Editor

Splenic infarction in thalassemia major

Letter to the Editor

Comment to the response to “Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome”

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits